Panbela announces issuance of new patent in china for claims of a novel process for the production of sbp-101

Minneapolis, sept. 26, 2023 (globe newswire) --  (nasdaq: pbla), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced an issue notification for the chinese patent 201980010826.7 titled “methods for producing (6s,15s)-3,8,13,18- tetraazaicosane-6,15-diol”.
PBLA Ratings Summary
PBLA Quant Ranking